Platelet-rich plasma reduces tear size in partial supraspinatus tendon tears compared to conventional steroid injection

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210428004

Enrollment

Registered

2021-04-28

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff injury Rotator cuff, platelet-rich plasma, PRP, MRI

Interventions

PRP injection to partial-tear rotator cuff Arthrex ACPTM Double Syringe System Blood drawn from subject Centrifuge blood 1500 rpm for 5 min PRP for injection Platelet conc. 300,000-500,000 / mL Collec

Experimental Biological/Vaccine,Active Comparator Drug

PRP,Corticosteroid injection

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age 18-85 years No underlying diseases Diagnosed partial-tear rotator cuff with conservative treatment > 3months

Exclusion criteria

Exclusion criteria: Inflammatory disease Nerve-related symptoms Malignancy Coagulopathy

Design outcomes

Primary

Measure	Time frame
Tear size 6 months MRI	—

Secondary

Measure	Time frame
Functional score 6 months American Shoulder and Elbow Score	—

Countries

Thailand

Contacts

Public ContactDanaithep Limskul

Chulalongkorn University

limskul.md@gmail.com0837913239

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026